- -

Metformin intake associates with better cognitive function in patients with Huntington's disease

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Metformin intake associates with better cognitive function in patients with Huntington's disease

Mostrar el registro sencillo del ítem

Ficheros en el ítem

Thumbnail
Nombre: Hervas-MarinForne ...
Tamaño: 1.643Mb
Formato: PDF
Descripción: Versión editorial
Abrir
dc.contributor.author Hervás-Marín, David es_ES
dc.contributor.author Fornés-Ferrer, Victoria es_ES
dc.contributor.author Gómez-Escribano, Ana Pilar es_ES
dc.contributor.author Dolores Sequedo, Maria es_ES
dc.contributor.author Peiró, Carmen es_ES
dc.contributor.author Millán, José María es_ES
dc.contributor.author Vázquez-Manrique, Rafael P. es_ES
dc.date.accessioned 2024-02-05T19:02:59Z
dc.date.available 2024-02-05T19:02:59Z
dc.date.issued 2017-06-20 es_ES
dc.identifier.issn 1932-6203 es_ES
dc.identifier.uri http://hdl.handle.net/10251/202353
dc.description.abstract [EN] Huntington's disease (HD) is an inherited, dominant neurodegenerative disorder caused by an abnormal expansion of CAG triplets in the huntingtin gene (htt). Despite extensive efforts to modify the progression of HD thus far only symptomatic treatment is available. Recent work suggests that treating invertebrate and mice HD models with metformin, a well-known AMPK activator which is used worldwide to treat type 2-diabetes, reduces mutant huntingtin from cells and alleviates many of the phenotypes associated to HD. Herein we report statistical analyses of a sample population of participants in the Enroll-HD database, a world-wide observational study on HD, to assess the effect of metformin intake in HD patients respect to cognitive status using linear models. This cross-sectional study shows for the first time that the use of metformin associates with better cognitive function in HD patients. es_ES
dc.description.sponsorship RVM holds a "Miguel Servet" fellowship (Ref: CP11/00090) funded by the Institute de Salud Carlos III (ISCIII, Madrid, Spain), a grant from the ISCIII (PI14/00949) and Fundacio Telemarato de la TV3 (ref: 559). The funds from the ISCIII are partially supported by the European Regional Development Fund. RVM is also a Marie Curie fellow (CIG322034, EU). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the Enroll-HD Study team, its collaborators (see haps://www.enroll-hd,org/for-researchers/technical-support/ for Site Principle Investigators and Study Coordinators) and study participants. Enroll-HD is a longitudinal observational study for Huntington's disease families intended to accelerate progress towards therapeutics; it is sponsored by CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to developing therapeutics for HD. Enroll-HD would not be possible without the vital contribution of the research participants and their families. es_ES
dc.language Inglés es_ES
dc.publisher Public Library of Science es_ES
dc.relation.ispartof PLoS ONE es_ES
dc.rights Reconocimiento (by) es_ES
dc.subject Metformin es_ES
dc.subject.classification ESTADISTICA E INVESTIGACION OPERATIVA es_ES
dc.title Metformin intake associates with better cognitive function in patients with Huntington's disease es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1371/journal.pone.0179283 es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MICINN//CP11%2F00090/ES/CP11%2F00090/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MINECO//PI14%2F00949/ES/Estrategias terapéuticas contra la toxicidad producida por péptidos y RNA codificados por el alelo mutante de htt en la enfermedad de Huntington/ es_ES
dc.rights.accessRights Abierto es_ES
dc.contributor.affiliation Universitat Politècnica de València. Escuela Politécnica Superior de Alcoy - Escola Politècnica Superior d'Alcoi es_ES
dc.description.bibliographicCitation Hervás-Marín, D.; Fornés-Ferrer, V.; Gómez-Escribano, AP.; Dolores Sequedo, M.; Peiró, C.; Millán, JM.; Vázquez-Manrique, RP. (2017). Metformin intake associates with better cognitive function in patients with Huntington's disease. PLoS ONE. 12(6):1-11. https://doi.org/10.1371/journal.pone.0179283 es_ES
dc.description.accrualMethod S es_ES
dc.relation.publisherversion https://doi.org/10.1371/journal.pone.0179283 es_ES
dc.description.upvformatpinicio 1 es_ES
dc.description.upvformatpfin 11 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 12 es_ES
dc.description.issue 6 es_ES
dc.identifier.pmid 28632780 es_ES
dc.identifier.pmcid PMC5478119 es_ES
dc.relation.pasarela S\508228 es_ES
dc.contributor.funder European Commission es_ES
dc.contributor.funder Ministerio de Ciencia e Innovación es_ES
dc.contributor.funder Ministerio de Economía y Competitividad es_ES


Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem